TrovaGene Inc (NASDAQ:TROV) gapped up prior to trading on Monday . The stock had previously closed at $0.24, but opened at $0.25. TrovaGene shares last traded at $0.26, with a volume of 2656609 shares changing hands.
TROV has been the topic of a number of research reports. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a research note on Wednesday, October 18th. cut TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The business had revenue of $0.12 million for the quarter.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.